SIGNATOPE provides project-oriented assay development services to pharmaceutical and academic partners.
More than 150 proprietary antibodies towards short terminal epitopes have been developed so far. This allows us to enrich thousands of different peptides in the digested proteome of a single species. The combination of SIGNATOPE´s antibodies and the high sensitivity and specificity of mass spectrometers allows us rapid assay development.
Moreover, SIGNATOPE provides unique monoclonal and polyclonal antibody development services for the application mass spectrometry-based immunoassays (e.g. ImmunoMALDI, ...). Unique epitope selection tools, affinity screening methods, clone selection based on slow koff, antibody purification strategies and array-based epitope characterization tools provide unbeaten success rates.